Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Social media

Yanti De Visser

BSc, MSc

MSc by Research

Research summary

BRCA1 and BRCA2 play a key role in double-strand break repair mediated by homologous recombination. Deficiency in one of these proteins results in DNA damage accumulation with subsequent genome instability and increased risk of cancer development. Treatment of these BRCA1/2-deficient cells and tumours with G-quadruplex ligands are proven to be effective earlier in our lab, potentially by innate immune response activation. Another drug, taxol-based, already used for the treatment of various cancers in the clinic, might have a synergistic effect in a co-treatment with a G-quadruplex ligand by accelerating innate immune response activation and induced apoptosis. It is my aim to investigate this synergy and the underlying mechanism of innate immune response activation.



I obtained my BSc in Bioscience engineering at the University of Antwerp, Belgium, in 2017. I then continued my academic career with an MSc in Bioscience engineering: Cell and gene biotechnology at Ghent University, Belgium. I conducted my Master dissertation "Characterisation of less toxic variants of L-asparaginase for treatment of leukaemia" in collaboration with the University of Illinois at Chicago, USA in 2019.

Research groups